The contribution of prostaglandins versus prostacyclin in ventricular remodeling during heart failure

Life Sciences

Volumn 89, Issue 19-20, 2011, Pages 671-676

  Harding, Pamela ^a   Murray, David B ^b  

^a HENRY FORD HOSPITAL   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

Cardiac; Eicosanoid; Fibrosis; Hypertrophy; Myocardium; Prostaglandin receptor; Remodeling

Indexed keywords

ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; BERAPROST; CALCINEURIN; CALCIUM ION; CYCLOOXYGENASE 2; DEXAMETHASONE; FLUPROSTENOL; G PROTEIN COUPLED RECEPTOR; GLUCOCORTICOID RECEPTOR; ILOPROST; INOSITOL PHOSPHATE; LIPOCALIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NITROPRUSSIDE SODIUM; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHENYLALANINE; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTAGLANDIN D; PROSTAGLANDIN E2; PROSTAGLANDIN F; PROSTANOID; PROTEINASE ACTIVATED RECEPTOR 2; ROSIGLITAZONE; THROMBOXANE A2; TRANSFORMING GROWTH FACTOR BETA;

AGING; ATHEROSCLEROSIS; BLOOD VESSEL TONE; CALCIUM CELL LEVEL; CARDIOVASCULAR SYSTEM; CELL DIFFERENTIATION; CELL GROWTH; CELLULAR STRESS RESPONSE; DISEASE EXACERBATION; ENZYME INHIBITION; EX VIVO STUDY; EXTRACELLULAR MATRIX; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART RATE; HEART VENTRICLE REMODELING; HEART WEIGHT; IN VIVO STUDY; KIDNEY BLOOD FLOW; LONGITUDINAL STUDY; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE;

ANIMALS; EPOPROSTENOL; FIBROSIS; HEART FAILURE; HUMANS; HYPERTROPHY; PROSTAGLANDINS; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 80055024878     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2011.07.025     Document Type: Review

References (82)

1. A. Abbate, D. Santini, G.G. Biondi-Zoccai, S. Scarpa, F. Vasaturo, and G. Liuzzo Cyclo-oxygenase-2 (COX-2) expression at the site of recent myocardial infarction: friend or foe? Heart 90 4 2004 440 443
2. J.W. Adams, D.S. Migita, M.K. Yu, R. Young, M.S. Hellickson, and F.E. Castro-Vargas Prostaglandin F2 alpha stimulates hypertrophic growth of cultured neonatal rat ventricular myocytes J Biol Chem 271 2 1996 1179 1186
3. J.W. Adams, V.P. Sah, S.A. Henderson, and J.H. Brown Tyrosine kinase and c-Jun NH2-terminal kinase mediate hypertrophic responses to prostaglandin F2alpha in cultured neonatal rat ventricular myocytes Circ Res 83 2 1998 167 178
4. AOCS LIPID LIBRARY. Eicosanoids And Related Compounds - An Introduction. 4-20-2011. Ref Type: Internet Communication.
5. K. Birkenmeier, I. Janke, W.H. Schunck, C. Trimpert, T. Krieg, and M. Landsberger Prostaglandin receptors mediate effects of substances released from ischaemic rat hearts on non-ischaemic cardiomyocytes Eur J Clin Invest 38 12 2008 902 909
6. E.C. Chan, G.J. Dusting, N. Guo, H.M. Peshavariya, C.J. Taylor, and R. Dilley Prostacyclin receptor suppresses cardiac fibrosis: role of CREB phosphorylation J Mol Cell Cardiol 49 2 2010 176 185
7. K. Chen, J. Chen, D. Li, X. Zhang, and J.L. Mehta Angiotensin II regulation of collagen type I expression in cardiac fibroblasts: modulation by PPAR-gamma ligand pioglitazone Hypertension 44 5 2004 655 661
8. N. Degousee, S. Fazel, D. Angoulvant, E. Stefanski, S.C. Pawelzik, and M. Korotkova Microsomal prostaglandin E2 synthase-1 deletion leads to adverse left ventricular remodeling after myocardial infarction Circulation 117 13 2008 1701 1710
9. Q.N. Diep, K. Benkirane, F. Amiri, J.S. Cohn, D. Endemann, and E.L. Schiffrin PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats J Mol Cell Cardiol 36 2 2004 295 304
10. Y. Eguchi, N. Eguchi, H. Oda, K. Seiki, Y. Kijima, and Y. Matsu-Ura Expression of lipocalin-type prostaglandin D synthase (beta-trace) in human heart and its accumulation in the coronary circulation of angina patients Proc Natl Acad Sci USA 94 26 1997 14689 14694
11. H. Francois, K. Athirakul, L. Mao, H. Rockman, and T.M. Coffman Role for thromboxane receptors in angiotensin-II-induced hypertension Hypertension 43 2 2004 364 369
12. H. Francois, K. Athirakul, D. Howell, R. Dash, L. Mao, and H.S. Kim Prostacyclin protects against elevated blood pressure and cardiac fibrosis Cell Metab 2 3 2005 201 207
13. M.A. Frias, M.C. Rebsamen, C. Gerber-Wicht, and U. Lang Prostaglandin E2 activates Stat3 in neonatal rat ventricular cardiomyocytes: a role in cardiac hypertrophy Cardiovasc Res 73 1 2007 57 65
14. M.B. Frungieri, S. Weidinger, V. Meineke, F.M. Kohn, and A. Mayerhofer Proliferative action of mast-cell tryptase is mediated by PAR2, COX2, prostaglandins, and PPARgamma: possible relevance to human fibrotic disorders Proc Natl Acad Sci USA 99 23 2002 15072 15077
15. M.B. Frungieri, M. Albrecht, R. Raemsch, and A. Mayerhofer The action of the mast cell product tryptase on cyclooxygenase-2 (COX2) and subsequent fibroblast proliferation involves activation of the extracellular signal-regulated kinase isoforms 1 and 2 (erk1/2) Cell Signal 17 4 2005 525 533
16. M.W. Goldblatt Constituents of human seminal plasma Biochem J 29 6 1935 1346 1357
17. S.A. Gupte, and T. Okada Prostaglandins and nitric oxide mediate superoxide-induced myocardial contractile dysfunction in isolated rat hearts J Mol Cell Cardiol 33 6 2001 1107 1117
18. F. Han, K. Takeda, K. Ishikawa, M. Ono, F. Date, and S. Yokoyama Induction of lipocalin-type prostaglandin D synthase in mouse heart under hypoxemia Biochem Biophys Res Commun 385 3 2009 449 453
19. G.H. Hao, X.L. Niu, D.F. Gao, J. Wei, and N.P. Wang Agonists at PPAR-gamma suppress angiotensin II-induced production of plasminogen activator inhibitor-1 and extracellular matrix in rat cardiac fibroblasts Br J Pharmacol 153 7 2008 1409 1419
20. A. Hara, K. Yuhki, T. Fujino, T. Yamada, K. Takayama, and S. Kuriyama Augmented cardiac hypertrophy in response to pressure overload in mice lacking the prostaglandin I2 receptor Circulation 112 1 2005 84 92
21. A. Hara, K. Yuhki, T. Fujino, T. Yamada, K. Takayama, and S. Kuriyama Augmented cardiac hypertrophy in response to pressure overload in mice lacking the prostaglandin I2 receptor Circulation 112 1 2005 84 92
22. P. Harding, and M.C. Lapointe Prostaglandin E2 increases cardiac fibroblast proliferation and increases cyclin D expression via EP1 receptor Prostaglandins Leukot Essent Fatty Acids 84 5-6 2011 147 152
23. P. Harding, X.P. Yang, J. Yang, E. Shesely, Q. He, and M.C. Lapointe Gene expression profiling of dilated cardiomyopathy in older male EP4 knockout mice Am J Physiol Heart Circ Physiol 298 2 2010 H623 H632
24. P. Harding, X.P. Yang, Q. He, and M.C. Lapointe Lack of microsomal prostaglandin E synthase-1 reduces cardiac function following angiotensin II infusion Am J Physiol Heart Circ Physiol 300 3 2011 H1053 H1061
25. J.L. Herlong, and T.R. Scott Positioning prostanoids of the D and J series in the immunopathogenic scheme Immunol Lett 102 2 2006 121 131
26. K. Hishikari, J. Suzuki, M. Ogawa, K. Isobe, T. Takahashi, and M. Onishi Pharmacological activation of the prostaglandin E2 receptor EP4 improves cardiac function after myocardial ischaemia/reperfusion injury Cardiovasc Res 81 1 2009 123 132
27. T. Hohlfeld, T.P. Zucker, J. Meyer, and K. Schror Expression, function, and regulation of E-type prostaglandin receptors (EP3) in the nonischemic and ischemic pig heart Circ Res 81 5 1997 765 773
28. T. Hohlfeld, J. Meyer-Kirchrath, Y.C. Vogel, and K. Schror Reduction of infarct size by selective stimulation of prostaglandin EP(3)receptors in the reperfused ischemic pig heart J Mol Cell Cardiol 32 2 2000 285 296
29. M. Iglarz, R.M. Touyz, E.C. Viel, P. Paradis, F. Amiri, and Q.N. Diep Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension Hypertension 42 4 2003 737 743
30. C.M. Jenkins, A. Cedars, and R.W. Gross Eicosanoid signalling pathways in the heart Cardiovasc Res 82 2 2009 240 249
31. Z. Jia, X. Guo, H. Zhang, M.H. Wang, Z. Dong, and T. Yang Microsomal prostaglandin synthase-1-derived prostaglandin E2 protects against angiotensin II-induced hypertension via inhibition of oxidative stress Hypertension 52 5 2008 952 959
32. Z. Jia, T. Aoyagi, and T. Yang mPGES-1 protects against DOCA-salt hypertension via inhibition of oxidative stress or stimulation of NO/cGMP Hypertension 55 2 2010 539 546
33. N. Jovanovic, M. Pavlovic, V. Mircevski, Q. Du, and A. Jovanovic An unexpected negative inotropic effect of prostaglandin F2alpha in the rat heart Prostaglandins Other Lipid Mediat 80 1-2 2006 110 119
34. T. Kaneshige, Y. Saida, R. Tanaka, A. Soda, A. Fukushima, and N. Ida Effect of long-term administration of a prostacyclin analogue (beraprost sodium) on myocardial fibrosis in Dahl rats J Vet Med Sci 69 12 2007 1271 1276
35. J. Kaplan, J.A. Cook, M. O'connor, and B. Zingarelli Peroxisome proliferator-activated receptor gamma is required for the inhibitory effect of ciglitazone but not 15-deoxy-Delta 12,14-prostaglandin J2 on the NFkappaB pathway in human endothelial cells Shock 28 6 2007 722 726
36. I. Kehat, J. Davis, M. Tiburcy, F. Accornero, M.K. Saba-El-Leil, and M. Maillet Extracellular signal-regulated kinases 1 and 2 regulate the balance between eccentric and concentric cardiac growth Circ Res 108 2 2011 176 183
37. G. Kemming, H. Kisch-Wedel, M. Flondor, C. Hofstetter, W. Kreyling, and E. Thein Improved ventricular function during inhalation of PGI(2) aerosol partly relies on enhanced myocardial contractility Eur Surg Res 37 1 2005 9 17
38. H. Kisch-Wedel, G. Kemming, F. Meisner, M. Flondor, W.M. Kuebler, and S. Bruhn The prostaglandins epoprostenol and iloprost increase left ventricular contractility in vivo Intensive Care Med 29 9 2003 1574 1583
39. H. Kisch-Wedel, G. Kemming, F. Meisner, M. Flondor, S. Bruhn, and C. Koehler Effect of prostaglandin I2 analogues on left ventricular diastolic function in vivo Eur J Pharmacol 517 3 2005 208 216
40. T. Kobayashi, Y. Tahara, M. Matsumoto, M. Iguchi, H. Sano, and T. Murayama Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice J Clin Invest 114 6 2004 784 794
41. P. Kunapuli, J.A. Lawson, J.A. Rokach, J.L. Meinkoth, and G.A. Fitzgerald Prostaglandin F2alpha (PGF2alpha) and the isoprostane, 8, 12-iso-isoprostane F2alpha-III, induce cardiomyocyte hypertrophy. Differential activation of downstream signaling pathways J Biol Chem 273 35 1998 22442 22452
42. J. Lai, H. Jin, R. Yang, J. Winer, W. Li, and R. Yen Prostaglandin F2 alpha induces cardiac myocyte hypertrophy in vitro and cardiac growth in vivo Am J Physiol 271 6 Pt 2 1996 H2197 H2208
43. M.C. Lapointe, M. Mendez, A. Leung, Z. Tao, and X.P. Yang Inhibition of cyclooxygenase-2 improves cardiac function after myocardial infarction in the mouse Am J Physiol Heart Circ Physiol 286 4 2004 H1416 H1424
44. F. Levi-Schaffer, and A.M. Piliponsky Tryptase, a novel link between allergic inflammation and fibrosis Trends Immunol 24 4 2003 158 161
45. A.M. Lincoff, K. Wolski, S.J. Nicholls, and S.E. Nissen Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials JAMA 298 10 2007 1180 1188
46. S. Manzano-Fernandez, J.L. Januzzi Jr., M. Boronat-Garcia, J.C. Bonaque-Gonzalez, Q.A. Truong, and F.J. Pastor-Perez beta-trace protein and cystatin C as predictors of long-term outcomes in patients with acute heart failure J Am Coll Cardiol 57 7 2011 849 858
47. M. Martin, J. Meyer-Kirchrath, G. Kaber, C. Jacoby, U. Flogel, and J. Schrader Cardiospecific overexpression of the prostaglandin EP3 receptor attenuates ischemia-induced myocardial injury Circulation 112 3 2005 400 406
48. M. Mendez, and M.C. Lapointe Trophic effects of the cyclooxygenase-2 product prostaglandin E(2) in cardiac myocytes Hypertension 39 2 Pt 2 2002 382 388
49. M. Mendez, and M.C. Lapointe PGE2-induced hypertrophy of cardiac myocytes involves EP4 receptor-dependent activation of p42/44 MAPK and EGFR transactivation Am J Physiol Heart Circ Physiol 288 5 2005 H2111 H2117
50. J. Meyer-Kirchrath, M. Martin, C. Schooss, C. Jacoby, U. Flogel, and A. Marzoll Overexpression of prostaglandin EP3 receptors activates calcineurin and promotes hypertrophy in the murine heart Cardiovasc Res 81 2 2009 310 318
51. N.G. Nikitakis, H. Siavash, C. Hebert, M.A. Reynolds, A.W. Hamburger, and J.J. Sauk 15-PGJ2, but not thiazolidinediones, inhibits cell growth, induces apoptosis, and causes downregulation of Stat3 in human oral SCCa cells Br J Cancer 87 12 2002 1396 1403
52. S.E. Nissen, and K. Wolski Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality Arch Intern Med 170 14 2010 1191 1201
53. T. Ogata, T. Miyauchi, S. Sakai, M. Takanashi, Y. Irukayama-Tomobe, and I. Yamaguchi Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway J Am Coll Cardiol 43 8 2004 1481 1488
54. H. Otani, H. Otani, and D.K. Das Positive inotropic effect and phosphoinositide breakdown mediated by arachidonic acid and prostaglandin F2 alpha J Pharmacol Exp Ther 244 3 1988 844 851
55. R. Pettipher The roles of the prostaglandin D(2) receptors DP(1) and CRTH2 in promoting allergic responses Br J Pharmacol 153 Suppl 1 2008 S191 S199
56. M.C. Polidori, D. Pratico, K. Savino, J. Rokach, W. Stahl, and P. Mecocci Increased F2 isoprostane plasma levels in patients with congestive heart failure are correlated with antioxidant status and disease severity J Card Fail 10 4 2004 334 338
57. K. Ponicke, C. Giessler, M. Grapow, I. Heinroth-Hoffmann, K. Becker, and B. Osten FP-receptor mediated trophic effects of prostanoids in rat ventricular cardiomyocytes Br J Pharmacol 129 8 2000 1723 1731
58. K. Ponicke, C. Giessler, M. Grapow, I. Heinroth-Hoffmann, K. Becker, and B. Osten FP-receptor mediated trophic effects of prostanoids in rat ventricular cardiomyocytes Br J Pharmacol 129 8 2000 1723 1731
59. R. Pop-Busui, G.W. Evans, H.C. Gerstein, V. Fonseca, J.L. Fleg, and B.J. Hoogwerf Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial Diabetes Care 33 7 2010 1578 1584
60. J.Y. Qian, P. Harding, Y. Liu, E. Shesely, X.P. Yang, and M.C. Lapointe Reduced cardiac remodeling and function in cardiac-specific EP4 receptor knockout mice with myocardial infarction Hypertension 51 2 2008 560 566
61. S. Radovanovic, M. Krotin, D.V. Simic, J. Mimic-Oka, A. Savic-Radojevic, and M. Pljesa-Ercegovac Markers of oxidative damage in chronic heart failure: role in disease progression Redox Rep 13 3 2008 109 116
62. G. Rossoni, B. Manfredi, V. De G.C., A.T. Brini, G. Polvani, and M.G. Clement Nitric oxide and prostacyclin pathways: an integrated mechanism that limits myocardial infarction progression in anaesthetized rats Pharmacol Res 53 4 2006 359 366
63. R. Schuligoi, M. Grill, A. Heinemann, B.A. Peskar, and R. Amann Sequential induction of prostaglandin E and D synthases in inflammation Biochem Biophys Res Commun 335 3 2005 684 689
64. A. Sivarajah, M.C. Mcdonald, and C. Thiemermann The cardioprotective effects of preconditioning with endotoxin, but not ischemia, are abolished by a peroxisome proliferator-activated receptor-gamma antagonist J Pharmacol Exp Ther 313 2 2005 896 901
65. C.A. Souders, S.L. Bowers, and T.A. Baudino Cardiac fibroblast: the renaissance cell Circ Res 105 12 2009 1164 1176
66. R. Stratton, V. Rajkumar, M. Ponticos, B. Nichols, X. Shiwen, and C.M. Black Prostacyclin derivatives prevent the fibrotic response to TGF-beta by inhibiting the Ras/MEK/ERK pathway FASEB J 16 14 2002 1949 1951
67. K. Takayama, K. Yuhki, K. Ono, T. Fujino, A. Hara, and T. Yamada Thromboxane A2 and prostaglandin F2alpha mediate inflammatory tachycardia Nat Med 11 5 2005 562 566
68. K. Takayama, K. Yuhki, K. Ono, T. Fujino, A. Hara, and T. Yamada Thromboxane A2 and prostaglandin F2alpha mediate inflammatory tachycardia Nat Med 11 5 2005 562 566
69. S. Tokudome, M. Sano, K. Shinmura, T. Matsuhashi, S. Morizane, and H. Moriyama Glucocorticoid protects rodent hearts from ischemia/reperfusion injury by activating lipocalin-type prostaglandin D synthase-derived PGD2 biosynthesis J Clin Invest 119 6 2009 1477 1488
70. Y. Urade, Y. Eguchi, N. Eguchi, Y. Kijima, Y. Matsuura, and H. Oda Secretion of lipocalin-type prostaglandin D synthase (beta-trace) from human heart to plasma during coronary circulation Adv Exp Med Biol 469 1999 49 54
71. U.S. Von Euler Prostaglandin, historical remarks Prog Lipid Res 20 1981 xxxi xxxv
72. M.J. Wacker, S.R. Best, L.M. Kosloski, C.J. Stachura, R.L. Smoot, and C.B. Porter Thromboxane A2-induced arrhythmias in the anesthetized rabbit Am J Physiol Heart Circ Physiol 290 4 2006 H1353 H1361 Apr, Epub 2005 Dec 9
73. N.S. Wayman, Y. Hattori, M.C. Mcdonald, H. Mota-Filipe, S. Cuzzocrea, and B. Pisano Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size FASEB J 16 9 2002 1027 1040
74. R. Wolfram, A. Oguogho, B. Palumbo, and H. Sinzinger Enhanced oxidative stress in coronary heart disease and chronic heart failure as indicated by an increased 8-epi-PGF(2alpha) Eur J Heart Fail 7 2 2005 167 172
75. C.Y. Xiao, A. Hara, K. Yuhki, T. Fujino, H. Ma, and Y. Okada Roles of prostaglandin I(2) and thromboxane A(2) in cardiac ischemia-reperfusion injury: a study using mice lacking their respective receptors Circulation 104 18 2001 2210 2215
76. C.Y. Xiao, K. Yuhki, A. Hara, T. Fujino, S. Kuriyama, and T. Yamada Prostaglandin E2 protects the heart from ischemia-reperfusion injury via its receptor subtype EP4 Circulation 109 20 2004 2462 2468
77. T. Yamada, T. Fujino, K. Yuhki, A. Hara, H. Karibe, and O. Takahata Thromboxane A2 regulates vascular tone via its inhibitory effect on the expression of inducible nitric oxide synthase Circulation 108 19 2003 2381 2386
78. S.F. Yew, K.A. Reeves, and B. Woodward Effects of prostaglandin F2 alpha on intracellular pH, intracellular calcium, cell shortening and L-type calcium currents in rat myocytes Cardiovasc Res 40 3 1998 538 545
79. H. Yu, A.M. Gallagher, P.M. Garfin, and M.P. Printz Prostacyclin release by rat cardiac fibroblasts: inhibition of collagen expression Hypertension 30 5 1997 1047 1053
80. K. Yuhki, H. Kashiwagi, F. Kojima, J. Kawabe, and F. Ushikubi Roles of prostanoids in the pathogenesis of cardiovascular diseases Int Angiol 29 2 Suppl 2010 19 27
81. K. Yuhki, F. Kojima, H. Kashiwagi, J. Kawabe, T. Fujino, and S. Narumiya Roles of prostanoids in the pathogenesis of cardiovascular diseases: novel insights from knockout mouse studies Pharmacol Ther 129 2 2011 195 205
82. B. Zingarelli, P.W. Hake, P. Mangeshkar, M. O'connor, T.J. Burroughs, and G. Piraino Diverse cardioprotective signaling mechanisms of peroxisome proliferator-activated receptor-gamma ligands, 15-deoxy-Delta12,14-prostaglandin J2 and ciglitazone, in reperfusion injury: role of nuclear factor-kappaB, heat shock factor 1, and Akt Shock 28 5 2007 554 563